CD19 and precursor B-cell acute lymphoblastic leukemia: While we focused on advancing AML treatment, we expect that epitope engineering can be applied to other haematological malignancies characterized by the paucity of safely actionable antigens, such as T lymphoblastic leukaemia or relapsed CD19− B cell acute lymphoblastic leukaemia.